Pyxis plummets following phase 1 data on candidate for head and neck cancer
Source: SeekingAlpha
2025-12-18 11:53:31 ET
More on Pyxis Oncology
- Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma - Slideshow
- Seeking Alpha’s Quant Rating on Pyxis Oncology
- Historical earnings data for Pyxis Oncology
- Financial information for Pyxis Oncology
Read the full article on Seeking Alpha
For further details see:
Pyxis plummets following phase 1 data on candidate for head and neck cancer
Pyxis Oncology Inc.
NASDAQ: PYXS
PYXS Trading
5.59% G/L:
$1.51 Last:
151,960 Volume:
$1.47 Open:
PYXS Latest News
February 03, 2026 06:45:00 am
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
January 12, 2026 10:14:09 am
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
January 08, 2026 10:36:00 am
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard
PYXS Stock Data
$126,496,274
71,256,534
0.76%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
